HeartFlow announced today that it closed a $215 million Series F funding round led by Bain Capital Life Sciences.
New investor Janus Henderson Investors also contributed to the round. Participating existing investors included Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management. J.P. Morgan acted as the sole placement agent to HeartFlow.
Mountain View, California-based HeartFlow said the funding enables it to meet the growing demand for its commercial products. The company develops the non-invasive HeartFlow FFRCT analysis. It uses artificial intelligence to create a personalized three-dimensional heart model. Commercial availability spans the U.S., UK, Canada, Europe and Japan.
HeartFlow also develops AI-powered Plaque analysis and Roadmap Analysis products, which the FDA cleared in October 2022. The company designed this technology around coronary computed tomography angiography (CCTA). It now offers non-invasive coronary artery anatomy, physiology and plaque information based on CCTA.
Other uses for the funds include supporting clinical evidence and advancing the product portfolio. HeartFlow aims to help physicians diagnose coronary artery disease (CAD) and guide treatment decisions.
“HeartFlow has built a strong intellectual property portfolio, brought to market the only combined anatomy, physiology and plaque analysis to help diagnose and treat heart disease, and is now in over 725 hospital systems worldwide with over 180,000 patients served to date,” said John Farquhar, CEO of HeartFlow. “The oversubscription of our Series F funding round, particularly in the current market backdrop, is a strong validation of our technology, our team and the opportunity in front of us.
“We appreciate the support of our investors, both existing and new, who share HeartFlow’s vision to build a new standard of care for people at risk of heart disease.”
